Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Recombinant DNA01:09

Recombinant DNA

Overview
Recombinant DNA01:09

Recombinant DNA

Overview
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages.

Frontiers in pharmacology·2026
Same author

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.

ACS materials letters·2026
Same author

A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.

ACS materials letters·2026
Same author

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.

Biomaterials advances·2026
Same author

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates.

Materials today. Bio·2026
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Recombinant Protein Drugs: A 2025 Update.

Hèctor López-Laguna1,2,3, Eloi Parladé3,4, Marianna T P Favaro2,3

  • 1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195, Sant Cugat del Vallès, Spain.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Recombinant protein therapeutics are evolving into highly engineered, multifunctional platforms. Innovations in production, engineering, and regulation are driving the next generation of advanced biologic drugs.

More Related Videos

Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach
11:20

Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach

Published on: October 16, 2014

Related Experiment Videos

Last Updated: May 15, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach
11:20

Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach

Published on: October 16, 2014

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Development

Background:

  • Recombinant protein therapeutics have advanced from simple replacement drugs to complex, multifunctional platforms.
  • Innovations in synthetic biology, host cell engineering, and bioprocess optimization are key drivers of this evolution.
  • Next-generation protein formats include bispecific antibodies, nanobodies, and fusion proteins with diverse therapeutic applications.

Purpose of the Study:

  • To provide a 2025 update on the field of recombinant protein drugs.
  • To integrate recent advances in production platforms, protein engineering, and regulatory science.
  • To outline how these technological advancements are shaping the future of biologics.

Main Methods:

  • Review of recent literature and industry trends in recombinant protein drug development.
  • Analysis of innovations in host systems (microbial, mammalian, plant-based) for protein production.
  • Examination of modular protein engineering strategies for novel therapeutic formats.
  • Assessment of evolving regulatory frameworks and manufacturing models.

Main Results:

  • Significant progress in host systems enabling high-fidelity, scalable, and safe protein production.
  • Development of diverse next-generation protein formats with expanded therapeutic potential.
  • Adaptation of regulatory pathways for complex and personalized biologics.
  • Emergence of decentralized and flexible manufacturing models.

Conclusions:

  • Recombinant protein drugs are transitioning into versatile platforms for functional reprogramming.
  • Technological advancements across production, engineering, and regulation are accelerating biologic innovation.
  • The field is poised for the development of sophisticated biologics targeting a wide range of diseases.